CYP2A6 and metabolic dysfunction-associated steatohepatitis: Importantly, the authors found that activities of CYP1A2 and CYP2C19 decreased whereas metabolic capacities of CYP2A6 and CYP2C9 increased during progression from healthy livers to steatosis and non-alcoholic steatohepatitis (NASH).